NCT03617913View on ClinicalTrials.gov

Avelumab in Combination With Fluorouracil and Mitomycin or Cisplatin and Radiation Therapy in Treating Participants With Muscle-Invasive Bladder Cancer

PHASE2CompletedINTERVENTIONAL
Enrollment

2

Participants

Timeline

Start Date

September 19, 2018

Primary Completion Date

November 14, 2019

Study Completion Date

July 27, 2020

Conditions
Bladder Carcinoma Infiltrating the Muscle of the Bladder WallStage II Bladder Cancer AJCC v8Stage II Renal Pelvis Cancer AJCC v8Stage II Ureter Cancer AJCC v8Stage II Urethral Cancer AJCC v8Stage III Bladder Cancer AJCC v8Stage III Renal Pelvis Cancer AJCC v8Stage III Ureter Cancer AJCC v8Stage III Urethral Cancer AJCC v8Stage IIIA Bladder Cancer AJCC v8Stage IIIB Bladder Cancer AJCC v8Urethral Urothelial Carcinoma
Interventions
DRUG

Avelumab

Given IV

DRUG

Cisplatin

Given IV

DRUG

Fluorouracil

Given IV

DRUG

Mitomycin

Given IV

OTHER

Quality-of-Life Assessment

Ancillary studies

RADIATION

Radiation Therapy

Undergo RT

Trial Locations (3)

32224

Mayo Clinic in Florida, Jacksonville

55905

Mayo Clinic, Rochester

85054

Mayo Clinic in Arizona, Scottsdale

Sponsors

Lead Sponsor

Mayo Clinic
All Listed Sponsors
collaborator

National Cancer Institute (NCI)

NIH

lead

Mayo Clinic

OTHER